Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Xarelto

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    82 result(s) found for: Xarelto. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2014-000565-47 Sponsor Protocol Number: BAY59-7939/14372 Start Date*: 2014-07-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with...
    Medical condition: Venous Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) IE (Completed) FR (Completed) FI (Completed) HU (Completed) SE (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004484-31 Sponsor Protocol Number: Riva-PCC Start Date*: 2014-01-10
    Sponsor Name:Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin
    Full Title: Rivaroxaban and PCC: Prothrombin Complex Concentrate in patients with bleeding complications related to Rivaroxaban
    Medical condition: blood coagulation disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10009728 Coagulation and bleeding analyses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004539-30 Sponsor Protocol Number: BAY59-7939/14373 Start Date*: 2012-10-23
    Sponsor Name:Bayer AG
    Full Title: 30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis
    Medical condition: venous thrombosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004507-13 Sponsor Protocol Number: ANT-006 Start Date*: 2021-03-02
    Sponsor Name:Anthos Therapeutics
    Full Title: A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial F...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001567-20 Sponsor Protocol Number: P161102J Start Date*: 2017-12-18
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002084-20 Sponsor Protocol Number: Version_1.0_MP_and_anticoagulants Start Date*: 2011-07-28
    Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
    Full Title: A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex...
    Medical condition: The effect of the used IMPs should be investigated in critically ill patients and healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005395-35 Sponsor Protocol Number: GatesMRI-COD-01-T01-01 Start Date*: 2020-12-16
    Sponsor Name:Bill & Melinda Gates Medical Research Institute
    Full Title: A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19
    Medical condition: Mild COVID-19 in people who are at high risk for moderate or severe disease due to age, body mass index (BMI) and comorbidities, many of which are also thrombotic risks.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-001190-40 Sponsor Protocol Number: P110150 Start Date*: 2018-05-16
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10036206 Portal vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002282-33 Sponsor Protocol Number: COVID-PREVENT Start Date*: 2020-10-01
    Sponsor Name:Charité - Universitaetsmedizin Berlin
    Full Title: Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)
    Medical condition: Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001657-28 Sponsor Protocol Number: CTHC002 Start Date*: 2014-01-23
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE)
    Medical condition: Acute low-risk pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) FI (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000648-16 Sponsor Protocol Number: BAY59-7939/19365 Start Date*: 2017-06-21
    Sponsor Name:Bayer AG
    Full Title: Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects
    Medical condition: Prevention and treatment of thromboembolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10043640 Thrombosis venous LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000609-18 Sponsor Protocol Number: BAY59-7939/19366 Start Date*: 2017-06-20
    Sponsor Name:Bayer AG
    Full Title: Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 20 mg granules for oral suspension rivaroxaban versus 20 mg tablets rivaroxaban under fed condition in healthy subjects
    Medical condition: Prevention and treatment of thromboembolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10043640 Thrombosis venous LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000958-36 Sponsor Protocol Number: RIDTS-Vers3-20Jan2016 Start Date*: 2016-08-18
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
    Full Title: RIDTS Study - Rivaroxaban for the treatment of symptomatic Isolated Distal deep vein Thrombosis
    Medical condition: SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10049915 Deep venous thrombosis distal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005158-73 Sponsor Protocol Number: SURPRISE-2011 Start Date*: 2012-04-11
    Sponsor Name:GWT-TUD GmbH
    Full Title: Superficial vein thrombosis (SVT) treated for forty-five days with Rivaroxaban versus Fondaparinux
    Medical condition: Lower extremity superficial vein thrombosis (SVT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002105-18 Sponsor Protocol Number: 333336666666666699 Start Date*: 2017-05-04
    Sponsor Name:Helsinki City Hospital Haartman
    Full Title: Laboratory measurement of direct oral anticoagulants on patients with atrial fibrillation
    Medical condition: Non-valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001975-30 Sponsor Protocol Number: BAY59-7939/17938 Start Date*: 2016-01-12
    Sponsor Name:Bayer AG
    Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ...
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017313-30 Sponsor Protocol Number: BAY59-7939/12892 Start Date*: 2010-06-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism
    Medical condition: Venous thromboembolism.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) IT (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003556-39 Sponsor Protocol Number: DARINA Start Date*: 2012-06-05
    Sponsor Name:Martini Hospital Groningen
    Full Title: A randomized pilot study comparing the safety of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after knee arthroplasty surgery. DARINA
    Medical condition: After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE). Two novel agents, dabigatran and rivaroxaban, recently gained market authorisation for pre...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004575-13 Sponsor Protocol Number: TRAPS-1.5 Start Date*: 2014-10-29
    Sponsor Name:Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova
    Full Title: A prospective, randomized clinical trial comparing Rivaroxaban vs warfarin in high risk patients with antiphospholipid syndrome (TRAPS).
    Medical condition: THROMBOEMBOLISM PREVENTION
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001845-15 Sponsor Protocol Number: TINCRBEL_study Start Date*: 2018-07-13
    Sponsor Name:Academic medical centre, department of internal medicine
    Full Title: EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study)
    Medical condition: Chronic intestinal failuyre (IF) is caused by large surgical bowel resection, severe motility, or absorption diseorders. These patientds require partial or total parenteral nutrition (PN and TPN, r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:10:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA